Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.
In the USA alone, approximately 61,000 new diagnoses of ductal intraepithelial neoplasia 1c-3 (DIN) are made each year. Around 10-20 % of the patients develop a recurrence, about 50 % of which are invasive. Prior studies have shown that invasive breast carcinomas positive for p16 or p53 have a higher frequency of recurrence and a more aggressive course; however, the co-expression of these markers across the entire spectrum of DIN and its potential correlation with grade of the lesions has not been studied previously. Immunohistochemical staining for p16 and p53 was evaluated on 262 DIN lesions from 211 cases diagnosed between 1991 and 2008. The lesions ranged from DIN1b (atypical intraductal hyperplasia) to DIN3 (DCIS, grade 3) and included 45 cases with associated invasive carcinoma. Frequency of staining for both p16 and p53 increased with increasing grade of DIN. Strong co-expression was found exclusively in higher grade DIN lesions (DIN2 and DIN3) particularly those associated with periductal stromal fibrosis and lymphocytic infiltrate. Strong co-expression was seen in 8 of 12 DIN3 lesions (67 %) associated with invasive carcinoma. In conclusion, co-expression of p16 and p53 increases with advancing grade of DIN and is maximal in high grade DIN lesions associated with invasive carcinoma, indicating a more aggressive phenotype. A distinctive variant of DIN with periductal fibrosis and lymphocytic infiltrate invariably falls into the high-grade category, based on either morphology or marker expression. Co-expression of p16/p53 may be of help in distinguishing between high-grade and low-grade DIN lesions.
Department of Pathology, School of Medicine, Yale University, New Haven, CT, USA.
Charles
C
Bechert
Department of Pathology, School of Medicine, Yale University, New Haven, CT, USA.|Department of Pathology, School of Medicine, Pusan National University, Busan, South Korea.
Jee-Yeon
JY
Kim
Department of Pathology, School of Medicine, Yale University, New Haven, CT, USA. tramm@oncology.au.dk.|Department of Pathology, Aarhus University Hospital, Nørrebrogade 44, Building 18, 8000, Aarhus C, Denmark. tramm@oncology.au.dk.
Trine
T
Tramm
Department of Pathology, School of Medicine, Yale University, New Haven, CT, USA.
Fattaneh A
FA
Tavassoli
D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000378:metabolism / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism*; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D011230:Precancerous Conditions / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
Ductal carcinoma in situ (DCIS); Ductal intraepithelial neoplasia (DIN); Immunohistochemistry; p16; p53
J Natl Cancer Inst. 2010 May 5;102(9):627-37
20427430
Ann Surg Oncol. 2010 May;17(5):1398-405
20049641
J Natl Cancer Inst. 1992 Jun 3;84(11):845-55
1317462
Br J Cancer. 1998 Dec;78(12):1661-8
9862580
Cancer Prev Res (Phila). 2010 May;3(5):579-87
20424132
Cancer Res. 2000 Dec 15;60(24):6788-93
11156366
Gene. 2001 Oct 17;277(1-2):15-30
11602342
Mod Pathol. 2006 Feb;19(2):264-71
16341146
Clin Cancer Res. 2000 Jul;6(7):2777-87
10914724
Hum Pathol. 2004 Dec;35(12):1524-30
15619212
Breast Cancer Res Treat. 2001 Dec;70(3):205-12
11804184
Breast Cancer Res Treat. 2008 Sep;111(1):27-44
17922188
Cancer Cell. 2007 Nov;12(5):479-91
17996651
J Pathol. 2001 May;194(1):35-42
11329139
J Cell Biochem. 2004 Nov 15;93(5):878-86
15449312
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8209-17
26339389
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6
9751761
Mod Pathol. 1998 Dec;11(12):1151-9
9872644
J Natl Cancer Inst. 2015 Sep 30;107(12 ):djv263
26424776
N Engl J Med. 2004 Apr 1;350(14):1430-41
15070793
Cell Death Differ. 2003 Apr;10(4):431-42
12719720
J Clin Oncol. 2007 Nov 20;25(33):5287-312
17954709
Cancer. 2007 Jan 1;109(1):25-32
17146782
Cancer Prev Res (Phila). 2011 Dec;4(12):1953-60
21920875
Am J Surg. 2005 Oct;190(4):521-5
16164913
Am J Surg Pathol. 2001 Jul;25(7):884-91
11420459
Mod Pathol. 1998 Feb;11(2):140-54
9504685
Hum Pathol. 2014 Apr;45(4):802-9
24560018
Oncogene. 2002 Feb 21;21(9):1316-24
11857075
Eur J Cancer. 2007 Jan;43(2):291-8
17118648
Anticancer Res. 1998 Nov-Dec;18(6A):4455-62
9891509
Oncology (Williston Park). 2015 Jun;29(6):446-58, 460-1
26089220
PLoS One. 2013 Oct 11;8(10):e76408
24146864
N Engl J Med. 2012 Mar 8;366(10 ):883-892
22397650
J Natl Cancer Inst. 2003 Nov 19;95(22):1692-702
14625260
J Natl Cancer Inst. 2010 Feb 3;102(3):161-9
20071686
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26742998
Breast Cancer Res Treat. 2001 May;67(1):61-70
11518467
Breast. 2000 Aug;9(4):177-86
14731991
Nature. 2004 Aug 12;430(7001):797-802
15306814
Ann Oncol. 2005 Nov;16(11):1723-39
15980158
Nature. 2000 Nov 16;408(6810):307-10
11099028
Am J Surg Pathol. 2009 Feb;33(2):163-75
18936692
Cancer. 1998 Jun 15;82(12):2382-90
9635531
J Med Genet. 2003 Aug;40(8):e102
12920094
Br J Cancer. 2001 Feb;84(4):539-44
11207051